CSF1R and familial pancreatic carcinoma: On this basis, a CSF1R inhibitor, Pexidartinib, is being combined with an anti-PD-L1 antibody, durvalumab, in a phase I study with expansion cohorts in colorectal and pancreatic cancer (NCT02777710).